Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography

Haemophilia

Volumn 12, Issue 6, 2006, Pages 598-604

  Young, G ^a   Blain, R ^a   Nakagawa, P ^a   Nugent, D J ^a  

^a CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

Author keywords

Haemophilia; Inhibitors; Thromboelastography; Treatment

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 ANTIBODY; DRUG ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADOLESCENT; ANALYZER; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BLEEDING; BLOOD ANALYSIS; BLOOD CLOTTING; BLOOD SAMPLING; CASE REPORT; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; HEMOPHILIA; HOSPITALIZATION; HUMAN; MALE; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY OF LIFE; SCHOOL CHILD;

FACTOR VIII; FACTOR X; HEMOPHILIA A; HEMOPHILIA B; HEMOSTATICS; HUMANS; MALE; RECOMBINANT PROTEINS; THROMBELASTOGRAPHY;

EID: 33750690191     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01319.x     Document Type: Article

References (11)

1. Darby SC, Keeling DM, Spooner RJ et.al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004; 2: 1047-54.
2. Young G, Aledort L. Therapy for haemophilia: Recent advances and goals for the future. Expert Opin Emerg Drugs 2005; 10: 173-84.
3. Parker ET, Craddock HN, Barrow RT, Lollar P. Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate:C in hemophilia A mice presensitized to human factor VIII. J Thromb Haemost 2004; 2: 605-11.
4. Key NS, Nelsestuen GL. Views on methods monitoring recombinant factor VIIa in inhibitor patients. Semin Hematol 2004; 41 (Suppl. 1): 51-4.
5. Schneiderman J, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors. Haemophilia 2004; 10: 347-51.
6. Wiinberg B, Jensen AL, Rojkjaer R, Johansson P, Kjelgaard-Hansen M, Kristensen AT. Validation of human recombinant tissue factor-activated thromboelastography on citrated whole blood from clinically healthy dogs. Vet Clin Pathol 2005; 34: 389-93.
7. Sorensen B, Ingerslev J. Tailoring haemostatic treatment to patient requirements -an update on monitoring haemostatic response using thromboelastography. Haemophilia 2005; 11 (Suppl. 1): 1-6.
8. Sorensen B, Ingerslev J. Thromboelastography and recombinant factor VIIa -haemophilia and beyond. Semin Hematol 2004; 41 (Suppl. 1): 140-4.
9. Ingerslev J, Poulsen LH, Sorensen B. Potential role of the dynamic properties of whole blood coagulation in assessment of dosage requirements in haemophilia. Haemophilia 2003; 9: 348-52.
10. Nugent D, Lovejoy A, Nakagawa P, Young G. Successful use of thromboelastography to determine dosing frequency of rFVIIa and FXIII. Blood 2003; 102 (Suppl. 1): 307a.
11. Allen GA, Wolberg AS, Oliver JA, Hoffman M, Roberts HR, Monroe DM. Impact of procoagulant concentration on rate, peak, and total thrombin generation in a model system. J Thromb Haemost 2004; 2: 402-13.